Xiangxue Pharmaceutical Co.,Ltd.

Equities

300147

CNE100000Y92

Pharmaceuticals

End-of-day quote Shenzhen S.E. 18:00:00 2024-05-16 EDT 5-day change 1st Jan Change
3.98 CNY -1.97% Intraday chart for Xiangxue Pharmaceutical Co.,Ltd. -10.76% -22.72%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Ji Qingsong agreed to acquire 18.87% stake in Hubei Tianji Pharmaceutical Co., Ltd. from Xiangxue Pharmaceutical Co.,Ltd. for CNY 200 million. CI
Xiangxue Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 959.884 million in funding CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Xiangxue Pharma Trims Losses in 2022 MT
China's COVID scare sparks run on flu medicines, test kits as far away as Australia RE
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Wuhan Yiyi Tongguan Enterprise Management Partnership (Limited Partnership) and Hubei Qingsong Yueyue Pharmaceutical Co., Ltd. agreed to acquire 35% stake in Hubei Tianji Pharmaceutical Co., Ltd. from Xiangxue Pharmaceutical Co.,Ltd. for CNY 385 million. CI
Xiangxue Pharmaceutical Co.,Ltd. Approves Board Elections CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Xiangxue Pharmaceutical Unlocks 3.4 Million Restricted Shares; Shares Rally 13% MT
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Xiangxue Pharma's Shareholder Scraps Stake Sale Plan CI
Guangdong Hengshu No. 1 Investment Partnership Enterprise (Limited Partnership) cancelled the acquisition of a 9.98% stake in Xiangxue Pharmaceutical Co.,Ltd. from Guangzhou Kunlun Investment Co., Ltd. CI
Xiangxue Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Xiangxue Pharmaceutical Co.,Ltd. signed the share transfer agreement to acquire Guangzhou Xiehe Precision Medical Co., Ltd. from Guangzhou Kunlun Investment Co., Ltd. for CNY 1.5 billion. CI
Guangdong Hengshu No. 1 Investment Partnership Enterprise (Limited Partnership) signed an agreement to acquire a 9.98% stake in Xiangxue Pharmaceutical Co.,Ltd. from Guangzhou Kunlun Investment Co., Ltd. for approximately CNY 390 million. CI
Suzhou Sirnaomics Biopharmaceuticals Co., Ltd signed share purchase agreement to acquire 4.2% stake in Guangzhou Nanotides Pharmaceuticals Co., Ltd. from Xiangxue Pharmaceutical Co.,Ltd. for CNY 2.2 million. CI
Chart Xiangxue Pharmaceutical Co.,Ltd.
More charts
XIANGXUE PHARMACEUTICAL CO.,LTD. is a China-based company principally engaged in the research, development, production and distribution of traditional Chinese medicines and herbal decoction pieces. The Company's main products include antiviral oral liquids, indigowoad root granules, Exocarpium Citri Reticulatae series Chinese patent drugs and herbal decoction pieces, among others. The Company is also involved in the manufacture and sale of medical devices, health products, soft drinks and biological products. The Company distributes its products in domestic market.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW